Login to Your Account



Other News To Note


Thursday, September 1, 2011
Titan Pharmaceuticals Inc., of South San Francisco, said the FDA confirmed an Oct. 25 pre-new drug application meeting regarding Probuphine, a subcutaneous implant formulation designed to deliver round-the-clock dosing of buprenorphine over six months following a single treatment for use in opioid dependence.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription